Safety Profile of Standardized Tranexamic Acid (TXA) Dosing in Rhytidectomy: A Retrospective Comparative Cohort Study

Clicks: 10
ID: 331737
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #101 of 116 articles by views in Aesthetic surgery journal

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Tranexamic acid (TXA) has been associated with reductions in intraoperative blood loss, early postoperative bleeding, time to drain removal, and postoperative ecchymosis in rhytidectomy. However, concerns regarding potential cutaneous and systemic complications persist, and interpretation of the literature is limited by variability in dosing, route of administration, and operative technique. As a result, the safety profile of TXA when mixed with local anesthetic in facelift surgery remains incompletely defined. OBJECTIVES: To evaluate complications associated with TXA mixed with local anesthetic using a standardized concentration and dosing protocol in patients undergoing combined facial and cervical rhytidectomy. METHODS: A retrospective comparative cohort study was conducted of a single surgeon's patients undergoing combined facial and cervical rhytidectomy under intravenous sedation, with and without the use of tranexamic acid (TXA) in local anesthetic infiltration (non-TXA vs TXA cohorts, 2012-2025). TXA was administered at defined concentrations of 9.1 mg/mL for incisional infiltration and 0.8 mg/mL in tumescent solution, with an average total dose of 582.6 mg per case. RESULTS: A total of 1,036 patients were included (TXA, n = 556; non-TXA, n = 480). TXA use was not associated with an increase in minor or major ischemic events or systemic complications. Distal flap vascular compromise requiring topical nitroglycerin occurred at similar rates providing an additional clinical measure of mild flap vascular stress. No cases of permanent nerve paralysis were observed. CONCLUSIONS: In this single-surgeon cohort using defined dosing, TXA mixed with local anesthetic was not associated with increased ischemic or systemic complications.
Reference Key
openalex_W7220682645 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sarah Langsdon, Samantha Moore, Phillip R. Langsdon
Journal Aesthetic surgery journal
Year 2026
DOI
10.1093/asj/sjag219
URL
https://doi.org/10.1093/asj/sjag219
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.